Compare PDC & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDC | MDXH |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | Japan | Belgium |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 21.1M |
| IPO Year | 2022 | 2021 |
| Metric | PDC | MDXH |
|---|---|---|
| Price | $3.09 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 57.9K | ★ 228.8K |
| Earning Date | 07-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.42 | $0.40 |
| 52 Week High | $8.40 | $5.33 |
| Indicator | PDC | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 40.80 | 68.02 |
| Support Level | $2.61 | $0.51 |
| Resistance Level | $4.54 | $3.79 |
| Average True Range (ATR) | 0.55 | 0.04 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 24.83 | 95.45 |
Perpetuals.com Ltd is a financial technology company bridging traditional financial markets with blockchain-based infrastructure. The group operates regulated financial market infrastructure at the intersection of traditional finance and digital assets. Its B2B offerings include capital markets technology delivered as SaaS and institutional-grade custody through Crypto Vault. For consumers, it provides compliant retail trading and prediction market platforms. The group's operations across the USA, Europe, and Asia develop software solutions that enable regulated trading venues to operate with 24/7 self-clearing and blockchain-based settlement technology, empowering institutions to compete in the evolving landscape of digital finance.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.